SARS-CoV-2 has a Ganglioside binding domain in its NTD 

A group from Aix-Marseille Université, France has reported that there is a ganglioside binding domain in SARS-CoV-2 NTD.

Residues 111-162 would be a ganglioside binding domain, and the binding could be inhibited by azithromycin which is a sugar-containing macrolide antibiotic which has some ganglioside mimicry properties, and also by 4A8 antibody that has been characterized in convalescent Covid-19 patients recognizes a discontinuous epitope of the NTD.

The figure blow shows an idea that the NTD binding to gangliosides induces the coalescence of lipid rafts together with a local modulation of membrane curvature that may facilitate the recruitment of the ACE-2 receptor.